779199-69-8

Usage

Uses

Used in Organic Synthesis:
Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate is used as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structure and reactivity make it a valuable chemical building block.
Used in Medicinal Chemistry:
Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate is used as a chemical building block for the development of pharmaceuticals and biologically active molecules. Its cyclopropane moiety can impart unique properties and activities to the compounds it is incorporated into, making it an interesting and valuable chemical building block.

Upstream product

• 111751-72-5 methyl 2-(4'-benzyloxyphenyl)propenoate 
• 68641-16-7 (4-benzyloxy-phenyl)-acetic acid methyl ester 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 
• 779206-51-8 1-(4-methoxyphenyl)cyclopropanecarboxylic acid methyl ester 

Downstream Products

• 936727-39-8 1-(4-hydroxy-3,5-diiodophenyl)cyclopropanecarboxylic acid methyl ester 
• 936727-45-6 1-(2,3-dihydrobenzofuran-5-yl)cyclopropanecarboxylic acid 
• 1428900-38-2 1-{4-[3-(4-fluorophenoxy)-5-{[(4-hydroxy-4-isobutyl-1-piperidinyl)carbonyl]amino}phenoxy]phenyl}cyclopropanecarboxylic acid 
• 952664-59-4 1-[4-(2-carboxyethoxy)phenyl]cyclopropanecarboxylic acid methyl ester 
• 936727-40-1 1-[3,5-diiodo-4-(2-methyl-allyloxy)phenyl]cyclopropanecarboxylic acid methyl ester 
• 936727-44-5 1-(benzofuran-5-yl)cyclopropanecarboxylic acid 
• 952664-58-3 1-[4-(2-tert-butoxycarbonyl-ethoxy)phenyl]cyclopropanecarboxylic acid methyl ester 

Relevant academic research and scientific papers

Site-Selective C?H Oxygenation via Aryl Sulfonium Salts

Herein, we report a two-step process forming arene C?O bonds in excellent site-selectivity at a late-stage. The C?O bond formation is achieved by selective introduction of a thianthrenium group, which is then converted into C?O bonds using photoredox chemistry. Electron-rich, -poor and -neutral arenes as well as complex drug-like small molecules are successfully transformed into both phenols and various ethers. The sequence differs conceptually from all previous arene oxygenation reactions in that oxygen functionality can be incorporated into complex small molecules at a late stage site-selectively, which has not been shown via aryl halides.

BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME

Provided is a compound showing excellent antifungal activity against Trichophyton fungus, which is a major causative microorganism of superficial mycosis, and high effectiveness on diseases caused by Trichophyton fungi. A biaryl derivative represented by the formula (I) or a salt thereof: wherein ring A is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered ring heteroaryl (ring A may be further condensed to form an optionally substituted fused ring); Q is CH2, C=O, NH, O, S or the like; X1, X2 and X3 are CR1 or N; Y is CH or N; Z is CR2b or N; R2a and R2b are each a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group, a C1-C6 haloalkyl group or the like; R2a and R2b may form, together with carbon atoms bonded thereto, an optionally substituted carbocycle, or an optionally substituted heterocycle.

PHARMACEUTICALS COMPRISING BIARYL DERIVATIVES OR SALTS THEREOF

PROBLEM TO BE SOLVED: To provide compounds with excellent antimycotic activity against Trichophyton. SOLUTION: The invention provides pharmaceuticals comprising biaryl derivatives represented by general formula (I) or salts thereof, where ring A is optionally substituted phenyl or the like; Q is CH2 or the like; X1, X2 and X3 are CR1 or the like; and Y is CH or N. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Compounds that modulate PPAR activity and methods of preparation

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.